| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2ca2e4410855da087e11bf3eea8933fa |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D498-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5365 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5365 |
| filingDate |
2017-05-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_003b50ac65f21017901c89a136cb84de
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ba1a315eb173065fb5ad342762416ab8 |
| publicationDate |
2018-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20180134401-A |
| titleOfInvention |
For example, as selective BACE1 inhibitors for the treatment of Alzheimer's disease, N- [3- [2-amino-5- (1,1-difluoroethyl) -4,4a, 5,7-tetrahydrofuro [ (Trifluoromethyl) pyridine-2-carboxamide and its (4aR, 5S, 7aS) -isomer |
| abstract |
The present invention provides, for example, a pharmaceutical composition comprising N- [3- [2-amino-5- (1,1-difluoroethyl) -4 Yl) -4-fluoro-phenyl] -5- (trifluoromethyl) pyridine-2- Carboxamide, i.e. the compound of formula I: Or a pharmaceutically acceptable salt thereof, and especially its (4aR, 5S, 7aS) isomer. |
| priorityDate |
2016-05-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |